Business · 29/08/2006

FDA Amends Notice of Cardiovascular and Renal Drugs Advisory Committee Meeting

The US Food and Drug Administration (FDA) is updating the meeting details of the Cardiovascular and Renal Drugs Advisory Committee, originally announced on August 1, 2006, to reflect changes in the agenda and correcting minor errors in the document, including the spelling of 'TRASYLOL' and 'aprotinin'.